NEWS
Go back
ARCHIMED buys Denmark’s DermaPharm A/S, a leading developer and manufacturer of skincare products
October
15,
2025
Headquartered in Fårup, Denmark and founded in 1980, DermaPharm develops and manufactures hypoallergenic, environmentally-friendly suncare, skincare, and haircare products, offering both its own branded products and private-label solutions for third parties. DermaPharm products are sold throughout the retail, hospital and healthcare sectors in Scandinavia and beyond. Its own Derma brand is the market leader in sunscreen in Denmark and a leading brand within the ‘nothing in its category’ globally.
“DermaPharm represents a rare opportunity to acquire a clean label, strategically positioned suncare and skincare developer with exceptional innovation, development, and manufacturing knowhow,” says Jean Yves Desmottes, Partner at ARCHIMED.
DermaPharm operates within the Consumer Health sector, one of ARCHIMED’s prioritized sectors and more specifically within the skincare sub-sector, a promising investment area identified with ARCHIMED’s proprietary MedSeg tool. MedSeg tracks and evaluates return potential in over 480 sub-segments of global healthcare.
For over four decades, DermaPharm has been developing, producing, and setting standards for environmentally-friendly, mild and skin-friendly skincare and suncare products. The company is recognized for its formulation excellence and transparency, regulatory expertise, and market-leading eco-certified product portfolio. It enjoys a strong reputation and leading position in Scandinavia. Scandinavia is the most advanced, regulation-driven skincare market in Europe.
Since its inception, DermaPharm has consistently achieved profitable growth. This performance is underpinned by long-term customer relationships and rising demand for eco-certified products, as well as DermaPharm’s capacity to manufacture innovative, high-quality, regulatory-compliant products.
“We’re facing a major increase in demand across our distribution channels for clean and eco-friendly products, amid heightened awareness of skin cancer risk,” says Mikkel Egelund Jensen, CEO of DermaPharm. “Partnering with ARCHIMED is key to addressing those needs internationally.”
ARCHIMED will work with Jensen and management – both reinvested significant proceeds from the sale in ARCHIMED’s DermaPharm purchase – to write the company’s next chapter of growth. Using its MedValue playbook, ARCHIMED will accelerate the group’s development, focusing on enriching and expanding the suncare products offer, increasing production, and reinforcing and broadening distribution to pharmacies, para-pharmacies (non-prescription offerings) and general retailers. The partners will also increase third party contractual work with skincare brands globally.
DermaPharm’s main suncare and skincare solutions positively affect health and patient outcomes, aligning DermaPharm with ARCHIMED’s impact investing policy.
We believe its cutting-edge, environmentally-friendly solutions have significant expansion potential not just in Scandinavia, but internationally.
Jean-Yves Desmottes, Partner at ARCHIMED
DermaPharm is the eighth investment of ARCHIMED’s MED III fund, which closed on €650 million in 2021. MED III typically partners with founders, owners, their families, and management teams.